Literature DB >> 23402364

Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213).

Birandra K Sinha1, Suchandra Bhattacharjee, Saurabh Chatterjee, JinJie Jiang, Ann G Motten, Ashutosh Kumar, Michael Graham Espey, Ronald P Mason.   

Abstract

Originally identified as an innate cytotoxin, nitric oxide ((·)NO) formation in tumors can influence chemotherapy and exacerbate cancer progression. Here, we examined the hypothesis that (·)NO generation contributes to cancer cell drug resistance toward the widely used anticancer drug Etoposide (VP-16). The UV-vis spectrum of VP-16 was not changed by exposure of VP-16 to (·)NO in aqueous buffer. In contrast, reddish-orange compound(s) characteristic of o-quinone- and nitroso-VP-16 were readily generated in a hydrophobic medium (chloroform) in an oxygen-dependent manner. Similar products were also formed when the VP-16 radical, generated from VP-16 and horseradish peroxidase/H2O2, was exposed directly to (·)NO in chloroform in the presence of oxygen. Separation and spectral analysis of VP-16 reaction extracts by electron spin resonance and UV-vis indicated the generation of the phenoxy radical and the o-quinone of VP-16, as well as putative nitroxide, iminoxyl, and other nitrogen oxide intermediates. Nitric oxide products of VP-16 displayed significantly diminished topoisomerase II-dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells. LPS-mediated induction of nitric oxide synthase in murine macrophages resulted in VP-16 resistance compared to Raw cells. Furthermore, (·)NO products derived from iNOS rapidly reacted with VP-16 leading to decreased DNA damage and cytotoxicity. Together, these observations suggest that the formation of (·)NO in tumors (associated macrophages) can contribute to VP-16 resistance via the detoxification of VP-16.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23402364      PMCID: PMC3697829          DOI: 10.1021/tx300480q

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  59 in total

1.  Transformations of 2,6-diisopropylphenol by NO-derived nitrogen oxides, particularly peroxynitrite.

Authors:  M Cudic; C Ducrocq
Journal:  Nitric Oxide       Date:  2000-04       Impact factor: 4.427

2.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.

Authors:  Sharon A Glynn; Brenda J Boersma; Tiffany H Dorsey; Ming Yi; Harris G Yfantis; Lisa A Ridnour; Damali N Martin; Christopher H Switzer; Robert S Hudson; David A Wink; Dong H Lee; Robert M Stephens; Stefan Ambs
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

3.  DNA topoisomerases as targets for cancer therapy.

Authors:  W E Ross
Journal:  Biochem Pharmacol       Date:  1985-12-15       Impact factor: 5.858

Review 4.  Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer.

Authors:  Stefan Ambs; Sharon A Glynn
Journal:  Cell Cycle       Date:  2011-02-15       Impact factor: 4.534

5.  DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.

Authors:  B K Sinha; N Haim; L Dusre; D Kerrigan; Y Pommier
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

6.  Nitrosative capacity of macrophages is dependent on nitric-oxide synthase induction signals.

Authors:  M G Espey; K M Miranda; R M Pluta; D A Wink
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

7.  Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach.

Authors:  V E Kagan; J C Yalowich; G G Borisenko; Y Y Tyurina; V A Tyurin; P Thampatty; J P Fabisiak
Journal:  Mol Pharmacol       Date:  1999-09       Impact factor: 4.436

8.  Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells.

Authors:  Yun Fan; Emanuel M Schreiber; Angela Giorgianni; Jack C Yalowich; Billy W Day
Journal:  Chem Res Toxicol       Date:  2006-07       Impact factor: 3.739

Review 9.  Macrophages define the invasive microenvironment in breast cancer.

Authors:  Jeffrey W Pollard
Journal:  J Leukoc Biol       Date:  2008-05-08       Impact factor: 4.962

10.  Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. Relationship to cytostasis induced in tumor cells by cytotoxic macrophages.

Authors:  M Lepoivre; J M Flaman; P Bobé; G Lemaire; Y Henry
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157

View more
  10 in total

1.  Nitric oxide: Friend or Foe in Cancer Chemotherapy and Drug Resistance: A Perspective.

Authors:  Birandra K Sinha
Journal:  J Cancer Sci Ther       Date:  2016-10-28

2.  Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Ronald P Mason
Journal:  Biochem Biophys Rep       Date:  2017-04-20

3.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

4.  Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.

Authors:  Birandra K Sinha; Lalith Perera; Ronald E Cannon
Journal:  Biomed Pharmacother       Date:  2019-10-09       Impact factor: 6.529

5.  Role of Oxygen and Nitrogen Radicals in the Mechanism of Anticancer Drug Cytotoxicity.

Authors:  Birandra Kumar Sinha
Journal:  J Cancer Sci Ther       Date:  2020-01-24

6.  Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma.

Authors:  Ke Wu; Xiao-Qing Sun; Cai-Qin Wang; Tian-Xiao Gao; Peng Sun; Yu Wang; Wen-Qi Jiang; Zhi-Ming Li; Jia-Jia Huang
Journal:  Cancer Med       Date:  2019-06-20       Impact factor: 4.452

7.  Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.

Authors:  Maximilian W Schenk; Sam Humphrey; A S Md Mukarram Hossain; Mitchell Revill; Sarah Pearsall; Alice Lallo; Stewart Brown; Samuel Bratt; Melanie Galvin; Tine Descamps; Cong Zhou; Simon P Pearce; Lynsey Priest; Michelle Greenhalgh; Anshuman Chaturvedi; Alastair Kerr; Fiona Blackhall; Caroline Dive; Kristopher K Frese
Journal:  Nat Commun       Date:  2021-11-17       Impact factor: 14.919

8.  Nitric oxide reverses drug resistance by inhibiting ATPase activity of p-glycoprotein in human multi-drug resistant cancer cells.

Authors:  Birandra K Sinha; Carl D Bortner; Ronald P Mason; Ronald E Cannon
Journal:  Biochim Biophys Acta Gen Subj       Date:  2018-09-01       Impact factor: 3.770

9.  Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.

Authors:  Ashutosh Kumar; Marilyn Ehrenshaft; Erik J Tokar; Ronald P Mason; Birandra K Sinha
Journal:  Biochim Biophys Acta       Date:  2016-04-17

10.  Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.

Authors:  Nilesh K Sharma; Ashutosh Kumar; Amrita Kumari; Erik J Tokar; Michael P Waalkes; Carl D Bortner; Jason Williams; Marilyn Ehrenshaft; Ronald P Mason; Birandra K Sinha
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.